Find Reports

Select Report Type

Reimbursement Review

Displaying 501 - 525 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Kisqali for Metastatic Breast ...	Kisqali	Ribociclib	pcodr_provfund_10112_ribocliclib_kisqali_mbc.pdf pcodr_ribociclib_kisqali_mbc_fn_rec.pdf pcodr_ribociclib_kisqali_mbc_fn_cgr.pdf pcodr_ribociclib_kisqali_mbc_fn_egr.pdf pcodr_ribociclib_kisqali_mbc_in_rec.pdf pcodr_ribociclib_kisqali_mbc_pagfdk.pdf pcodr_ribociclib_kisqali_mbc_fdk_novartis.pdf pcodr_ribociclib_kisqali_mbc_ptfdk.pdf pcodr_ribociclib_kisqali_mbc_clnfdk.pdf pcodr_ribociclib_kisqali_mbc_coi_pt.pdf pcodr_ribociclib_kisqali_mbc_coi_cln.pdf	Advanced or Metastatic Breast Cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 17, 2017	Apr 18, 2018	PC0112-000
Vectibix for Left Sided Metast...	Vectibix	Panitumumab	pcodr_profund_panitumumab_vectibix_ls_mcrc.pdf pcodr_panitumumab_vectibix_ls_mcrc_fn_rec.pdf pcodr_panitumumab_vectibix_ls_mcrc_fn_cgr.pdf pcodr_panitumumab_vectibix_ls_mcrc_fn_egr .pdf pcodr_panitumumab_vectibix_ls_mcrc_in_rec.pdf pcodr_panitumumab_vectibix_ls_mcrc_pagfdk.pdf pcodr_panitumumab_vectibix_ls_mcrc_fdk_amgen.pdf pcodr_panitumumab_vectibix_ls_mcrc_ptfdk.pdf pcodr_panitumumab_vectibix_ls_mcrc_clnfdk.pdf pcodr_panitumumab_vectibix_ls_mcrc_coi_pt.pdf pcodr_panitumumab_vectibix_ls_mcrc_coi_cln.pdf	Left Sided Metastatic Colorectal Cancer (mCRC)	Do not reimburse	Complete	Sep 8, 2017	Mar 29, 2018	PC0118-000
Alecensaro for Locally Advance...	Alecensaro	Alectinib	AlectinibAlecensaro_NSCLCsecondline10114ProvFunding.pdf pcodr_alectinib_alecensaro_nsclc_2ln_fn_rec.pdf pcodr_alectinib_alecensaro_nsclc_2ln_fn_cgr .pdf pcodr_alectinib_alecensaro_nsclc_2ln_fn_egr.pdf pcodr_alectinib_alecensaro_nsclc_2ln_in_rec.pdf pcodr_alectinib_alecensaro_nsclc_2ln_pagfdk.pdf pcodr_alectinib_alecensaro_nsclc_2ln_fdk_roche.pdf pcodr_alectinib_alecensaro_nsclc_2ln_coi_pt.pdf pcodr_alectinib_alecensaro_nsclc_2ln_coi_cln.pdf	Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 18, 2017	Mar 29, 2018	PC0114-000
tocilizumab	Actemra	tocilizumab	SR0534_Actemra_GCA_complete_Mar-27-18.pdf SR0534_ActemraGCA_CL_Report.pdf SR0534_Actemra_GCA_PE_Report.pdf SR0534_Actemra_GCA_PI_Submissions.pdf	Giant cell arteritis (GCA)	Reimburse with clinical criteria and/or conditions	Complete	Sep 25, 2017	Mar 27, 2018	SR0534-000
tenofovir alafenamide	Vemlidy	tenofovir alafenamide	SR0537_Vemlidy_complete_Mar-28-18.pdf SR0537_Vemlidy_CL_Report.pdf SR0537_Vemlidy_PE_Report.pdf SR0537_Vemlidy_PI_Submissions.pdf	Hepatitis B, chronic	Reimburse with clinical criteria and/or conditions	Complete	Sep 28, 2017	Mar 26, 2018	SR0537-000
Bavencio for metastatic Merkel...	Bavencio	Avelumab	AvelumabBavencio_metastaticMerkelcellcarcinoma10124_ProvFunding2019-11-19.pdf pcodr_avelumab_bavencio_mcc_fn_rec.pdf pcodr_avelumab_bavencio_mcc_fn_cgr.pdf pcodr_avelumab_bavencio_mcc_fn_egr.pdf pcodr_avelumab_bavencio_mmcc_in_rec.pdf pcodr_avelumab_bavencio_mcc_pagfdk.pdf pcodr_avelumab_bavencio_mcc_espa.pdf pcodr_avelumab_bavencio_mcc_clnfdk.pdf pcodr_avelumab_bavencio_mcc_coi_pt.pdf pcodr_avelumab_bavencio_mcc_coi_cln.pdf	metastatic Merkel Cell Carcinoma (mMCC)	Reimburse with clinical criteria and/or conditions	Complete	Oct 10, 2017	Mar 21, 2018	PC0124-000
Venclexta for Chronic Lymphocy...	Venclexta	Venetoclax	pcodr_profund_venetoclax_venclexta_cll.pdf pcodr_venetoclax_venclexta_cll_fn_rec.pdf pcodr_venetoclax_venclexta_cll_fn_cgr.pdf pcodr_venetoclax_venclexta_cll_fn_egr.pdf pcodr_venetoclax_venclexta_cll_in_rec.pdf pcodr_venetoclax_venclexta_cll_pagfdk.pdf pcodr_venetoclax_venclexta_cll_fdk_abbvie.pdf pcodr_venetoclax_venclexta_cll_ptfdk.pdf pcodr_venetoclax_venclexta_cll_clnfdk.pdf pcodr_venetoclax_venclexta_cll_coi_pt.pdf pcodr_venetoclax_venclexta_cll_coi_cln.pdf	Chronic Lymphocytic Leukemia	Reimburse with clinical criteria and/or conditions	Complete	Jul 10, 2017	Mar 2, 2018	PC0105-000
Keytruda for Metastatic Urothe...	Keytruda	Pembrolizumab	pcodr_provfund_pembrolizumab_keytruda_MUC.pdf pcodr_pembrolizumab_keytruda_muc_fn_rec.pdf pcodr_pembrolizumab_keytruda_muc_fn_cgr.pdf pcodr_pembrolizumab_keytruda_muc_fn_egr.pdf pcodr_pembrolizumab_keytruda_muc_in_rec.pdf pcodr_pembrolizumab_keytruda_muc_pagfdk.pdf pcodr_pembrolizumab_keytruda_muc_fdk_merck.pdf pcodr_pembrolizumab_keytruda_muc_clnfdk.pdf pcodr_pembrolizumab_keytruda_muc_coi_pt.pdf pcodr_pembrolizumab_keytruda_muc_coi_cln.pdf	For locally advanced or metastatic urothelial carcinoma	Reimburse with clinical criteria and/or conditions	Complete	Jul 24, 2017	Mar 2, 2018	PC0117-000
guselkumab	Tremfya	guselkumab	TS0001-PsO-Updated-Streamlined-Rec.pdf SR0530_Tremfya_complete_Feb-23-18.pdf SR0530_Tremfya_CL_Report.pdf SR0530_Tremfya_PE_Report.pdf SR0530_Tremfya_PI_Submissions.pdf	Psoriasis, moderate to severe plaque	Reimburse with clinical criteria and/or conditions	Complete	Aug 25, 2017	Feb 21, 2018	SR0530-000
nitisinone	Orfadin	nitisinone	SR0531_Orfadin_complete_Feb-23-18.pdf SR0531_Orfadin_CL_Report.pdf SR0531_Orfadin_PE_Report.pdf SR0531_Orfadin_PI.pdf	Hereditary tyrosinemia type 1	Reimburse with clinical criteria and/or conditions	Complete	Aug 29, 2017	Feb 21, 2018	SR0531-000
Adcetris for Hodgkin’s Lymphom...	Adcetris	Brentuximab Vedotin	pcodr_profund_brentuximab_adcetris_hl_post-asct_resub.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_rec.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_cgr.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_egr.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_in_rec.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_pagfdk.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_fdk_sgi.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_clnfdk.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_coi_pt.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_coi_cln.pdf	HL at high risk of relapse or progression post-ASCT	Reimburse with clinical criteria and/or conditions	Complete	Aug 10, 2017	Feb 21, 2018	PC0116-000
infliximab	Renflexis	infliximab	TS0001-PsO-Updated-Streamlined-Rec.pdf SE0532 Renflexis - CDEC Final Recommendation February 20, 2018(redacted)_for posting.pdf SE0532_Renflexis_Combined_Report.pdf SE0532_Renflexis_PI.pdf	rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis	Reimburse with clinical criteria and/or conditions	Complete	Sep 5, 2017	Feb 20, 2018	SE0532-000
Faslodex for Locally Advanced ...	Faslodex	Fulvestrant	pcodr_provfund_fulvestrant_faslodex_mbc.pdf pcodr_fulvestrant_faslodex_mbc_fn_rec.pdf pcodr_fulvestrant_faslodex_mbc_fn_cgr.pdf pcodr_fulvestrant_faslodex_mbc_fn_egr.pdf pcodr_fulvestrant_faslodex_mbc_in_rec.pdf pcodr_fulvestrant_faslodex_mbc_pagfdk.pdf pcodr_fulvestrant_faslodex_mbc_fdk_asz.pdf pcodr_fulvestrant_faslodex_mbc_ptfdk.pdf pcodr_fulvestrant_faslodex_mbc_clnfdk.pdf pcodr_fulvestrant_faslodex_mbc_coi_pt.pdf pcodr_fulvestrant_faslodex_mbc_coi_cln.pdf	Locally advanced or metastatic breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Jul 17, 2017	Feb 1, 2018	PC0110-000
cysteamine bitartrate	Procysbi	cysteamine bitartrate	SR0526_Procysbi_complete_Jan-26-18.pdf SR0526_Procysbi_CL_Report.pdf SR0526_Procysbi_PE_Report.pdf SR0526_Procysbi_Patient_Input.pdf SI0002-procysbi-drug-implementation-advice.pdf	Nephropathic cystinosis	Reimburse with clinical criteria and/or conditions	Complete	Aug 8, 2017	Jan 24, 2018	SR0526-000
migalastat	Galafold	migalastat	SR0522_Galafold_complete_Jan-26-18.pdf SR0522_Galafold_CL_Report.pdf SR0522_Galafold_PE_Report.pdf SR0522_Galafold_Patient_Input.pdf	Fabry Disease	Reimburse with clinical criteria and/or conditions	Complete	Jun 9, 2017	Jan 24, 2018	SR0522-000
sofosbuvir velpatasvir voxilap...	Vosevi	sofosbuvir velpatasvir voxilaprevir	SR0529_Vosevi_complete_Jan-25-18.pdf SR0529_Vosevi_CL_Report.pdf SR0529_Vosevi_PE_Report.pdf SR0529 Vosevi_Patient_Input.pdf	Hepatitis C, chronic	Reimburse with clinical criteria and/or conditions	Complete	Jul 28, 2017	Jan 23, 2018	SR0529-000
Apomorphine	Movapo	apomorphine hydrochloride	SR0527_Movapo_complete-Jan-25-18.pdf SR0527_Movapo_CL_Report.pdf SR0527_Movapo_PE_Report.pdf SR0527_Movapo_Patient_Input.pdf	Parkinson's disease	Reimburse with clinical criteria and/or conditions	Complete	Jul 6, 2017	Jan 23, 2018	SR0527-000
glecaprevir pibrentasvir	Maviret	glecaprevir pibrentasvir	SR0523_Maviret_complete-Jan-25-18.pdf SR0523_Maviret_CL_Report.pdf SR0523_Maviret_PE_Report.pdf SR0523_Maviret_Patient_Input.pdf	Hepatitis C, chronic	Reimburse with clinical criteria and/or conditions	Complete	Jun 9, 2017	Jan 23, 2018	SR0523-000
Pembrolizumab (Keytruda) class...	Keytruda	Pembrolizumab	pcodr_profund_pembrolizumab_keytruda_chl.pdf pcodr_pembrolizumab_keytruda_chl_fn_rec.pdf pcodr_pembrolizumab_keytruda_chl_fn_cgr.pdf pcodr_pembrolizumab_keytruda_chl_fn_egr.pdf pcodr_pembrolizumab_keytruda_chl_in_rec.pdf pcodr_pembrolizumab_keytruda_chl_pagfdk.pdf pcodr_pembrolizumab_keytruda_chl_fdk_merck.pdf pcodr_pembrolizumab_keytruda_chl_ptfdk.pdf pcodr_pembrolizumab_keytruda_chl_clnfdk.pdf pcodr_pembrolizumab_keytruda_chl_coi_pt.pdf pcodr_pembrolizumab_keytruda_chl_coi_cln.pdf	classical Hodgkin Lymphoma (cHL)	Reimburse with clinical criteria and/or conditions	Complete	Jul 7, 2017	Jan 5, 2018	PC0109-000
Onivyde for Metastatic Pancrea...	Onivyde	Irinotecan Liposome	pcodr_provfund_irinotecan_liposome_onivyde_mpc.pdf pcodr_irinotecan_liposome_onivyde_mpc_fn_rec.pdf pcodr_irinotecan_liposome_onivyde_mpc_fn_cgr.pdf pcodr_irinotecan_liposome_onivyde_mpc_fn_egr.pdf pcodr_irinotecan_liposome_onivyde_mpc_in_rec.pdf pcodr_irinotecan_liposome_onivyde_mpc_pagfdk.pdf pcodr_irinotecan_liposome_onivyde_mpc_clnfdk.pdf pcodr_irinotecan_liposome_onivyde_mpc_coi_pt.pdf pcodr_irinotecan_liposome_onivyde_mpc_coi_cln.pdf	Metastatic Pancreatic Cancer	Reimburse with clinical criteria and/or conditions	Complete	Apr 27, 2017	Jan 5, 2018	PC0107-000
nusinersen	Spinraza	nusinersen	SR0525_Spinraza_complete_Dec_22_17.pdf SR0525_Spinraza_CL_Report.pdf SR0525_Spinraza_PE_Report.pdf SR0525_Spinraza_Patient_Input.pdf	Spinal Muscular Atrophy	Reimburse with clinical criteria and/or conditions	Complete	Jun 28, 2017	Dec 22, 2017	SR0525-000
Rydapt for Acute Myeloid Leuke...	Rydapt	Midostaurin	pcodr_profund_midostaurin_rydapt_aml.pdf pcodr_midostaurin_rydapt_all_fn_rec.pdf pcodr_midostaurin_rydapt_all_fn_cgr.pdf pcodr_midostaurin_rydapt_all_fn_egr.pdf pcodr_midostaurin_rydapt_all_in_rec.pdf pcodr_midostaurin_rydapt_all_pagfdk.pdf pcodr_midostaurin_rydapt_all_fdk_novartis.pdf pcodr_midostaurin_rydapt_all_clnfdk.pdf pcodr_midostaurin_rydapt_all_coi_pt.pdf pcodr_midostaurin_rydapt_all_coi_cln.pdf	Acute Myeloid Leukemia	Reimburse	Complete	Jun 12, 2017	Dec 19, 2017	PC0108-000
Opdivo in combo with Yervoy fo...	Opdivo & Yervoy in combo	Nivolumab & Ipilimumab in combo	pcodr_profund_opdivo_yervoy_metmela.pdf pcodr_opdivo_yervoy_metmela_fn_rec.pdf pcodr_opdivo_yervoy_metmela_fn_cgr.pdf pcodr_opdivo_yervoy_metmela_fn_egr.pdf pcodr_opdivo_yervoy_metmela_in_rec.pdf pcodr_opdivo_yervoy_metmela_pagfdk.pdf pcodr_opdivo_yervoy_metmela_fdk_bms.pdf pcodr_opdivo_yervoy_metmela_ptfdk_mnc.pdf pcodr_opdivo_yervoy_metmela_ptfdk_sys.pdf pcodr_opdivo_yervoy_metmela_clfdk.pdf pcodr_opdivo_yervoy_metmela_coi_pt.pdf pcodr_opdivo_yervoy_metmela_coi_cl.pdf	Metastatic Melanoma	Reimburse with clinical criteria and/or conditions	Complete	Nov 30, 2016	Nov 30, 2017	PC0098-000
lixisenatide	Adlyxine	lixisenatide	SR0520_Adlyxine_complete_Nov-23-17.pdf SR0520_Adlyxine_CL_Report.pdf SR0520_Adlyxine_PE_Report.pdf SR0520_Adlyxine_PI_Submissions.pdf	Diabetes mellitus, Type 2	Reimburse with clinical criteria and/or conditions	Complete	May 29, 2017	Nov 23, 2017	SR0520-000
Evolocumab	Repatha	Evolocumab	cdr_SR0515_Repatha.pdf SR0515_Repatha_Resubmission_complete_Nov_24_17.pdf SR0515_Repatha_Resubmission_CL_Report.pdf SR0515_Repatha_Resubmission_PE_Report.pdf SR0515_Repatha_PI_Submissions.pdf	Primary hyperlipidemia and mixed dyslipidemia	Reimburse with clinical criteria and/or conditions	Complete	Feb 17, 2017	Nov 22, 2017	SR0515-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 501 - 525 of 600

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Non-invasive Nerve Stimulation Modalities for Migraine Pain: A Review of Clinical Effectiveness and Cost-effectiveness	RC1265 NINS for Migraine Final.pdf	Apr 27, 2020	Summary with Critical Appraisal	Completed	RC1265-000
Epinephrine Auto-Injectors for Anaphylaxis: A Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1269 Epinephrine Auto-Injector Final.pdf	Apr 27, 2020	Summary with Critical Appraisal	Completed	RC1269-000
Customized or Prefabricated Shoe Inserts for Chronic, Non-Cancer Pain: A Review of Clinical Effectiveness	RC1259 Orthotics Pain Final.pdf	Apr 20, 2020	Summary with Critical Appraisal	Completed	RC1259-000
Harmonization of Public Coverage Policies for Biologic Drugs in the Treatment of Rheumatoid Arthritis	Optimal Use 360 Report Utilization Review Budget Impact Analysis	Apr 17, 2020		Complete	HD0001-000
Skin Preparation for Injections: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines	RC1218 Skin Prep Injection Final corrected.pdf	Apr 16, 2020	Summary with Critical Appraisal	Completed	RC1218-000
Exercise for the Treatment of Ankle Sprain: A Review of Clinical Effectiveness and Guidelines	RC1261 - Exercise ankle sprain Final.pdf	Apr 13, 2020	Summary with Critical Appraisal	Completed	RC1261-000
Bacille Calmette-Guérin Vaccination: A Review of Clinical Effectiveness and Guidelines	RC1264 BCG Vaccination Final.pdf	Apr 6, 2020	Summary with Critical Appraisal	Completed	RC1264-000
Masks for Prevention of Influenza Transmission in Acute and Long-Term Care Settings: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines	RC1255 Influenza Masks Final.pdf	Mar 31, 2020	Summary with Critical Appraisal	Completed	RC1255-000
Intravitreal Dexamethasone Implants for Non-infectious Uveitis: A Review of Clinical Effectiveness, Cost-effectiveness, and Guidelines	RC1257-000 Ozurdex Uveitis Final.pdf	Mar 31, 2020	Summary with Critical Appraisal	Completed	RC1257-000
Body Weight Modification Interventions for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness	RC1258 Weight change pain Final.pdf	Mar 31, 2020	Summary with Critical Appraisal	Completed	RC1258-000
Serial X-Ray Radiography for the Diagnosis of Osteomyelitis: A Review of Diagnostic Accuracy, Clinical Utility, Cost-Effectiveness, and Guidelines	RC1256 Serial Radiography Osteomyelitis Final.pdf	Mar 23, 2020	Summary with Critical Appraisal	Completed	RC1256-000
Assessment of Dehydration and Oral Rehydration Therapy for Pediatric Patients with Dehydration: A Review of Clinical Effectiveness, Clinical Utility, and Guidelines	RC1240 ORT diagnosis treatment Final.pdf	Mar 23, 2020	Summary with Critical Appraisal	Completed	RC1240-000
Propranolol for Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness	RC1254 Propranolol PTSD Final.pdf	Mar 23, 2020	Summary with Critical Appraisal	Completed	RC1254-000
The Use of Real-World Evidence for Medical Device Assessment: An Environmental Scan		Mar 19, 2020			ES0344-000
Experiences with and Expectations of Robotic Surgical Systems: A Rapid Qualitative Review	RC1251 RSS for Gyno Uro Surgery Final.pdf	Mar 19, 2020	Summary with Critical Appraisal	Completed	RC1251-000
The Use of Real-World Evidence for Medical Device Assessment ─ An Environmental Scan		Mar 19, 2020			ES0344-000
Identification of Tuberculosis: A Review of the Guidelines	RC1236 TB identification Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1236-000
Drug-Resistant Tuberculosis: A Review of the Guidelines	RC1239 DR-TB guidelines Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1239-000
Treatment of Tuberculosis: A Review of Guidelines	RC1237 TB treatment guidelines Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1237-000
Tuberculosis in People with Compromised Immunity: A Review of Guidelines	RC1238 TB immunocompromised Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1238-000
Prevention of Tuberculosis: A Review of Guidelines	RC1223 TB prevention guidelines Final.pdf	Mar 18, 2020	Summary with Critical Appraisal	Completed	RC1223-000
Oral Rehydration Solutions versus Drink of Choice in Children with Dehydration: A Review of Clinical Effectiveness	RC1241 ORS Final.pdf	Mar 9, 2020	Summary with Critical Appraisal	Completed	RC1241-000
Local Anesthetic for Urinary Catheter Insertion: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1250 Urinary Catheter Anaesthetic Final.pdf	Mar 9, 2020	Summary with Critical Appraisal	Completed	RC1250-000
Botulinum Toxin for Temporomandibular Disorders: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1245 Botox for TMD Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1245-000
Manual Therapy for Persistent, Non-Cancer Back and Neck Pain: A Review of Clinical Effectiveness	RC1231 Manual Therapy Neck Back Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1231-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 501 - 525 of 2132

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Average Volume of MRI Exams Conducted per Hour Across Canada	Using data from the national Canadian Medical Imaging Inventory 2019 to 2020 survey, we calculated an average of MRI exams performed per hour across Canada	Average Volume of MRI Exams Conducted per Hour Across Canada	Jan 31, 2024	Health Technology Review	CMII Service	Completed	CM0008-000
Biologic Drugs for Severe Asthma		Final Report Summary Report	Jan 30, 2024	Health Technology Review	Technology Review	Completed	RE0047-000
Buprenorphine Formulations for Opioid Use Disorder		Buprenorphine Formulations for Opioid Use Disorder	Jan 30, 2024	Health Technology Review	Systematic Review	Completed	RE0051-000
nelarabine		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jan 26, 2024	Reimbursement Review		Complete	PC0307-000
CADTH Pharmaceutical Reviews Update — Issue 43			Jan 25, 2024	Reimbursement Review	Pharmaceutical Review Update
durvalumab and tremelimumab		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jan 25, 2024	Reimbursement Review		Complete	PC0308-000
The Safety of Niraparib in Ovarian Cancer	To give clinicians and policy-makers a better understanding of the niraparib’s risk profile, researchers conducted an observational study to look at how the safety and tolerability of niraparib in the real world compares with observations from seminal clinical trials.	Summary Report for Policy-Makers Summary Report for Clinicians Plain Language Summary Report Observational Study - The Safety of Niraparib in Ovarian Cancer Final Protocol	Jan 24, 2024	Health Technology Review	Observational Study	Active	OS0002-000
Unresectable Hepatocellular Carcinoma		Final Report	Jan 24, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0036-000
Chatbots in Health Care: Connecting Patients to Information		Chatbots in Health Care: Connecting Patients to Information	Jan 24, 2024	Horizon Scan	Emerging Health Technologies	Completed	EH0122-000
Ketamine for Adults With Treatment-Resistant Depression or Posttraumatic Stress Disorder: A 2023 Update	We conducted a review of the clinical effectiveness, cost-effectiveness, and evidence-based guidelines on the use of ketamine in adults with TRD or PTSD, to help guide decisions on the use of ketamine for managing these conditions.	Ketamine for Adults With Treatment-Resistant Depression or Posttraumatic Stress Disorder: A 2023 Update	Jan 23, 2024	Health Technology Review	Rapid Review	Completed	RC1522-000
axicabtagene ciloleucel		Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Jan 22, 2024	Reimbursement Review		Complete	PG0314-000
Endobronchial Valves for the Management of Severe Emphysema		Endobronchial Valves for the Management of Severe Emphysema	Jan 18, 2024	Health Technology Review	Rapid Review	Completed	RC1524-000
Ketorolac for Renal Colic		Ketorolac for Renal Colic	Jan 18, 2024	Health Technology Review	Rapid Review	Completed	RC1525-000
Immune checkpoint inhibitors for mutated non–small cell lung cancer			Jan 15, 2024	Health Technology Review	Observational Study	In Progress	OS0008-000
Artificial Intelligence– Enhanced Rapid Response Electroencephalography for the Identification of Nonconvulsive Seizure		Artificial Intelligence– Enhanced Rapid Response Electroencephalography for the Identification of Nonconvulsive Seizure	Jan 9, 2024	Horizon Scan	Health Technology Update	Completed	EN0054-000
Leucovorin Dosing for Gastrointestinal Cancer		Leucovorin Dosing for Gastrointestinal Cancer	Jan 9, 2024	Health Technology Review	Rapid Review	Completed	RC1518-000
Ketamine for Chronic Non-Cancer Pain: A 2023 Update		Ketamine for Chronic Non-Cancer Pain: A 2023 Update	Jan 9, 2024	Health Technology Review	Summary with Critical Appraisal	Completed	RC1521-000
Screening for Colorectal Cancer in Individuals Younger Than 50 Years		Screening for Colorectal Cancer in Individuals Younger Than 50 Years	Jan 8, 2024	Health Technology Review	Rapid Review with Expert Input	Completed	RD0069-000
Perspectives and Experiences Regarding the Creation of Arteriovenous Fistulas for Hemodialysis Access: A Rapid Qualitative Review		Perspectives and Experiences Regarding the Creation of Arteriovenous Fistulas for Hemodialysis Access: A Rapid Qualitative Review	Jan 8, 2024	Health Technology Review	Rapid Review	Completed	RC1519-000
Hernia Support Garments for Parastomal Hernia Following Ostomy Procedure		Hernia Support Garments for Parastomal Hernia Following Ostomy Procedure	Jan 8, 2024	Health Technology Review	Rapid Review	Completed	RC1520-000
Artificial Intelligence Decision Support Tools for End-of-life Care Planning Conversations		Artificial Intelligence Decision Support Tools for End-of-life Care Planning Conversations	Dec 22, 2023	Horizon Scan	Health Technology Update	Completed	EN0053-000
ChatGPT in Radiology: Appropriate Imaging and Workflow Efficiencies		ChatGPT in Radiology: Appropriate Imaging and Workflow Efficiencies	Dec 21, 2023	Health Technology Review	CMII Service	Completed	CM0009-000
Early Intervention Programs for Adolescents and Young Adults With Eating Disorders		Main Report Supporting Information Project Protocol	Dec 18, 2023	Health Technology Review	Health Technology Assessment	Completed	HT0040-000 - OP0552-000
Aging in Place	Our Health Technology Expert Review Panel convened to develop objective, impartial, trusted pan-Canadian guidance to inform decisions about which evidence-informed, equitable, aging in place initiatives across jurisdictions can support aging in place in Canada.	Evidence Assessment Report Supporting Information Summary of Engagement Activities Guidance	Dec 13, 2023	Health Technology Review	Optimal Use	Active	OP0555-000
Emerging Drugs for Relapsed or Refractory Peripheral T-Cell Lymphoma		Emerging Drugs for Relapsed or Refractory Peripheral T-Cell Lymphoma	Dec 12, 2023	Horizon Scan	Emerging Health Technologies	Completed	EH0119-000